Sangamo Therapeutics (SGMO) Earns Buy Rating from Analysts at Bank of America

Stock analysts at Bank of America assumed coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a note issued to investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 17th. Barclays reaffirmed a “buy” rating and set a $30.00 price target on shares of Sangamo Therapeutics in a research report on Sunday, February 25th. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, May 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $21.67.

Shares of Sangamo Therapeutics opened at $16.45 on Wednesday, according to MarketBeat Ratings. The stock has a market capitalization of $1.62 billion, a PE ratio of -23.50 and a beta of 2.89. Sangamo Therapeutics has a fifty-two week low of $7.35 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.78 and a current ratio of 4.78.



Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.52). The company had revenue of $12.60 million during the quarter, compared to the consensus estimate of $53.09 million. Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. Sangamo Therapeutics’s revenue for the quarter was up 270.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.23) earnings per share. equities research analysts anticipate that Sangamo Therapeutics will post -0.59 EPS for the current fiscal year.

In related news, VP Curt A. Herberts III sold 2,278 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $18.30, for a total transaction of $41,687.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $15.67, for a total transaction of $78,350.00. Following the sale, the chief financial officer now owns 12,250 shares in the company, valued at $191,957.50. The disclosure for this sale can be found here. Insiders have sold 47,656 shares of company stock worth $844,303 over the last quarter. Corporate insiders own 1.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Sangamo Therapeutics by 2.1% during the 4th quarter. BlackRock Inc. now owns 6,871,509 shares of the biopharmaceutical company’s stock valued at $112,691,000 after purchasing an additional 138,348 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Sangamo Therapeutics by 15.8% during the 4th quarter. Teachers Advisors LLC now owns 946,128 shares of the biopharmaceutical company’s stock worth $15,516,000 after acquiring an additional 128,743 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Sangamo Therapeutics by 58.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock worth $14,948,000 after acquiring an additional 336,107 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Sangamo Therapeutics by 23.0% during the 4th quarter. TIAA CREF Investment Management LLC now owns 883,382 shares of the biopharmaceutical company’s stock worth $14,487,000 after acquiring an additional 164,900 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Sangamo Therapeutics by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 840,104 shares of the biopharmaceutical company’s stock worth $13,777,000 after acquiring an additional 19,087 shares during the last quarter. Institutional investors and hedge funds own 56.14% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

The Fly

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply